Brief: FDA Grants Priority Review For Pfizer's Talzenna Plus Xtandi For The Treatment Of Metastatic Prostate Cancer
22/07/2026 22:50
BRIEF-FDA Grants Priority Review For Pfizer's Talzenna Plus Xtandi For The Treatment Of Metastatic Prostate Cancer July 22 (Reuters) - Pfizer Inc PFE.N:
FDA GRANTS PRIORITY REVIEW FOR PFIZER’S TALZENNA PLUS XTANDI FOR THE TREATMENT OF METASTATIC PROSTATE CANCER
PFIZER - FDA SETS PDUFA ACTION DATE FOR TALZENNA PLUS XTANDI IN Q4 2026
Source text: ID:nBw8mMBS9a
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Focus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Eli Lilly hits record high as healthcare stocks rally
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Major drugmakers turn to China for licensing deals